These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7474937)

  • 1. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.
    Kesari S; Randazzo BP; Valyi-Nagy T; Huang QS; Brown SM; MacLean AR; Lee VM; Trojanowski JQ; Fraser NW
    Lab Invest; 1995 Nov; 73(5):636-48. PubMed ID: 7474937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation, cell death, and neuronal differentiation in transplanted human embryonal carcinoma (NTera2) cells depend on the graft site in nude and severe combined immunodeficient mice.
    Miyazono M; Lee VM; Trojanowski JQ
    Lab Invest; 1995 Aug; 73(2):273-83. PubMed ID: 7637328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
    Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
    Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain.
    Kleppner SR; Robinson KA; Trojanowski JQ; Lee VM
    J Comp Neurol; 1995 Jul; 357(4):618-32. PubMed ID: 7673487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant.
    Randazzo BP; Kesari S; Gesser RM; Alsop D; Ford JC; Brown SM; Maclean A; Fraser NW
    Virology; 1995 Aug; 211(1):94-101. PubMed ID: 7645240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model.
    Miller CG; Fraser NW
    Cancer Res; 2000 Oct; 60(20):5714-22. PubMed ID: 11059765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase.
    Moriuchi S; Oligino T; Krisky D; Marconi P; Fink D; Cohen J; Glorioso JC
    Cancer Res; 1998 Dec; 58(24):5731-7. PubMed ID: 9865731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurons derived from a human teratocarcinoma cell line establish molecular and structural polarity following transplantation into the rodent brain.
    Trojanowski JQ; Mantione JR; Lee JH; Seid DP; You T; Inge LJ; Lee VM
    Exp Neurol; 1993 Aug; 122(2):283-94. PubMed ID: 8405265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
    Rainov NG; Kramm CM; Aboody-Guterman K; Chase M; Ueki K; Louis DN; Harsh GR; Chiocca A; Breakefield XO
    Cancer Gene Ther; 1996; 3(2):99-106. PubMed ID: 8729908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSV-tk gene therapy for human renal cell carcinoma in nude mice.
    Pulkkanen KJ; Parkkinen JJ; Laukkanen JM; Kettunen MI; Tyynela K; Kauppinen RA; Ala-Opas MY; Yla-Herttuala S
    Cancer Gene Ther; 2001 Jul; 8(7):529-36. PubMed ID: 11498775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
    Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
    Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
    Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
    Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
    Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
    Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.